Knowledge base · Peer-reviewed

ScaleWiki.

Peer-reviewed manuscripts on the G-Rex® platform — one citable page per paper, curated so you find the evidence that moves your cell & gene therapy program forward.

487Manuscripts indexed
14Cell types
Live indexContinuously updated

Showing 12 of 530 resources

Publications NK Cells G-Rex®6M Well Plate

Publication Date: January 1, 2023

Development of large-scale expansion protocol for NKG2C-positive NK cells for treatment of glioblastoma

NKG2C-positive NK cells, a small subset found preferentially in HCMV-seropositive donors, can be selectively expanded from peripheral blood on PC-3 feeder cells engineered to express IL-2, membrane-bound IL-15 and a single-chain trimeric HLA-E molecule. MACS-isolated NK cells were co-cultured with feeders at a 10:1 ratio in a G-Rex® 6M Well Plate for 11 days, with 5 × 10^5 feeder cells added on days 0, 3 and 7. Across 13 HCMV-seropositive donors the median expansion factor was 358.5 for NKG2C+ cells versus 49.1 for total NK cells, and NKG2C single-positive cells rose from a median of 5.4% to 55.3%. Expanded cells were mostly CD16+ (96.6%) and KIR2D+ (85.1%), and cells from eight donors ly…

Download Now →

Author: Alexander Becker, Susanne Michen +4 more

Publications VST Cells

Publication Date: December 23, 2022

AIMTM platform: A new immunotherapy approach for viral diseases

AIM nanoparticles, which mimic dendritic cell function, enriched and expanded multi-antigen-specific CD8+ T cells against EBV, HTLV-1 and HPV from HLA-A*02:01 healthy-donor leukapheresis cells. CD8+ T cells were enriched on a CliniMACS Prodigy and expanded for 14 days in a G-Rex® culture system. Summed antigen-specific frequencies were 95.45% and 69.23% for EBV in two donors, and 46.69% and 17.64% for HTLV-1. Over 90% of expanded cells had memory phenotypes. EBV-specific cells were polyfunctional and killed peptide-pulsed target cells. In four NEXI-003 validation runs, cells were 96.82% ± 2.89% CD3+/CD4− and killed HPV-16- and HPV-18-positive HLA-A2 tumor lines, with no significant killin…

Download Now →

Author: David Langan, Ruipeng Wang +11 more

Publications CAR T Cells, DC Cells, NK Cells, TIL Cells

Publication Date: December 15, 2022

Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies

Choosing a bioreactor for adoptive cell therapy manufacturing involves trade-offs between simplicity, scalability and automation, and no single platform suits every cell type. This review compares cell culture bags, G-Rex® flasks, rocking-motion, stirred-flask, stirred-tank and hollow-fiber bioreactors, and semi- or fully automated closed systems such as CliniMACS Prodigy and Cocoon. G-Rex® flasks are affordable, use standard laboratory equipment and expand TILs efficiently, yet producing a clinical TIL dose may require up to 30 flasks, complicating quality control. Rocking-motion bioreactors such as WAVE offer more automation and bag volumes up to 100 L, while automated closed systems cu…

Download Now →

Author: Irina Ganeeva, Ekaterina Zmievskaya +5 more

Publications CAR T Cells G-Rex®6 Well Plate

Publication Date: December 13, 2022

Development of an anti-CAR antibody response in SIV-infected rhesus macaques treated with CD4-MBL CAR/CXCR5 T cells

All nine rhesus macaques infused with SIV-specific CD4-MBL CAR/CXCR5 T cells developed anti-CAR IgG antibodies in serum, detected by a flow cytometry binding assay. Binding at 28 days after treatment ranged from 0.5% to 27% of target cells, and control animals showed none. Blocking CD4 with an antibody reduced or eliminated binding in all six animals tested, which points to the CD4 domains as the main antigenic site. Binding to CAR targets with the CD28 extracellular domain replaced was lower with serum from 2 of 3 animals. Most sera also triggered NK-cell degranulation in an ADCC assay. Antibody levels did not correlate significantly with CAR T cell persistence or with infused dose.

Download Now →

Author: Brianna C. Davey, Mary S. Pampusch +6 more

Publications CAR T Cells

Publication Date: December 1, 2022

Should we adopt an automated de-centralized model of chimeric antigen receptor- T cells manufacturing for low-and middle-income countries? A real world perspective

A decentralized, hospital-based model of autologous CAR-T manufacturing on automated closed platforms is argued to suit low- and middle-income countries such as India better than the centralized pharmaceutical model. The perspective contrasts the two models across apheresis, manufacturing and administration. Point-of-care production avoids cold-chain transport and cryopreservation, needs less cleanroom infrastructure and labour, and shortens arm-to-arm time. An Indian hospital facility estimated 35,100 USD per patient for preclinical validation runs on CliniMACS Prodigy, against about 475,000 USD for Kymriah in the United States. Barriers include absent national guidelines, scarce GMP-gra…

Download Now →

Author: Sharanya Ramakrishnan, Jeevan Kumar +4 more

Publications γδ T G-Rex®100M

Publication Date: November 16, 2022

Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells

Donor-derived γδ T cells can be expanded at large scale ex vivo using zoledronic acid, IL-2 and an engineered K-562 quadruplet artificial antigen-presenting cell (CD3scFv/CD137L/CD28scFv/IL15RA). Peripheral blood mononuclear cells from healthy donors were precultured for 7 days with 5 μM zoledronic acid and 300 IU/mL IL-2 in G-Rex® 100 flasks, depleted of αβ T cells, then cocultured with irradiated aAPCs. A 10:1 aAPC to γδ T cell ratio proved optimal. At day 10, three donors showed 730-, 132- and 633-fold expansion, reaching up to 3.2 × 10^9 γδ T cells, with αβ T cell contamination below 1%. Cryopreserved expanded cells from two donors killed CHO target cells in a real-time cytotoxicity a…

Download Now →

Author: Justin C. Boucher, Bin Yu +9 more

Publications VST Cells

Publication Date: November 15, 2022

Cytomegalovirus-Specific T Cells from Third-Party Donors Successfully Treated Refractory Cytomegalovirus Retinitis after Unrelated Umbilical Cord Blood Transplantation

Cytomegalovirus-specific T cells made from a third-party donor cleared refractory cytomegalovirus retinitis in a young man with acute myeloid leukemia after unrelated cord blood transplantation. Ganciclovir and foscarnet had not reduced viral load, and repeated intravitreal ganciclovir left the aqueous humor CMV-positive. The donor was the patient's brother, matched at 5 of 10 HLA loci. His blood was expanded in G-Rex® flasks, stimulated with pp65 peptides, and infused twice, on October 23 and November 3, 2020, with no cytokine release syndrome or graft-versus-host disease. Blood CMV PCR turned negative after the second infusion, aqueous humor was negative, and no relapse was seen at foll…

Download Now →

Author: Na Li, Guangyu Sun +13 more

Publications Other G-Rex®500M-CS

Publication Date: November 14, 2022

Safety and durability of AGT103-T autologous T cell therapy for HIV infection in a Phase 1 trial

In a Phase 1 trial in HIV-positive adults on antiretroviral therapy, a single infusion of autologous, lentivirus-modified AGT103-T cells enriched for Gag-specific CD4+ T cells caused no serious adverse events and raised Gag-specific immunity. Thirteen participants were enrolled and seven received product, five at low and two at high dose, after cyclophosphamide conditioning. Doses ranged from 2.00 to 21.33 million modified cells per kg. Of 16 adverse events, 14 were grade 1 and two grade 2. Modified cells peaked at Day 3 and were still detected in most participants at Day 180, with a median of 439 transgene copies per million PBMC. Gag-specific CD4+ T cells rose about 9 to 320-fold by Day…

Download Now →

Author: Nidal Muvarak, Haishan Li +5 more

Publications TCR T Cells G-Rex®100M-CS, G-Rex®24 Well Plate

Publication Date: November 10, 2022

Non-viral precision T cell receptor replacement for personalized cell therapy

A clinical-grade, non-viral CRISPR–Cas9 process replaced the endogenous T cell receptor with patient-specific neoantigen-specific TCRs (neoTCRs) in autologous T cells, and was tested in 16 patients with refractory solid cancers in a phase I dose-escalation trial. Each patient received up to three distinct neoTCR products across three dose levels. One patient had grade 1 cytokine release syndrome and one had grade 3 encephalitis; five patients had stable disease and eleven progressed. Infused neoTCR T cells were found in tumour biopsies, where 16 of 22 infused populations were detected. A culture medium change raised neoTCR knock-in efficiency from 13.4% to 23.0%. Median peak circulating n…

Download Now →

Author: Susan P. Foy, Kyle Jacoby +52 more

Publications NK Cells

Publication Date: November 8, 2022

Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

Allogeneic natural killer cell therapies for cancer have reached hundreds of clinical trials, and this review maps how they are sourced, manufactured and combined with other agents. As of December 2021, 420 NK cell trials had been registered, mostly Phase I and Phase I/II, with 36 non-engineered, 53 engineered, 62 non-engineered combination and 34 engineered combination trials analysed in detail. Peripheral blood was the most common source for non-engineered products (67%), while NK-92 cells dominated engineered combinations (71%). Products are expanded with media, serum, cytokines and feeder cells in flasks, bags and static or dynamic bioreactors. Reported safety is generally good, with…

Download Now →

Author: Nina Lamers-Kok, Denise Panella +7 more

Publications CAR T Cells

Publication Date: November 7, 2022

Chimeric antigen receptor structure and manufacturing of clinical grade CAR engineered cells using different bioreactors

This review surveys automated and semi-automated closed platforms for manufacturing clinical-grade CAR-engineered cells and identifies automation with closed systems as a main route to lowering cost of goods. It first outlines the four regions of a CAR: antigen-recognition, hinge or spacer, transmembrane and intracellular signalling domains. Platforms compared include the CliniMACS Prodigy, Cocoon, Quantum, Xuri W25, G-Rex® M series, CTS Rotea and stirred-tank bioreactors. The Quantum hollow-fiber bioreactor offers 2.1 m² of culture surface, equal to 120 T175 flasks; the Xuri W25 handles 300 mL to 25 L; and G-Rex® vessels scale from 2 to 500 cm², reaching CAR-T harvest densities of 20–30…

Download Now →

Author: Farhatullah Syed, Riad El Fakih +3 more

Publications CAR T Cells, Treg Cells G-Rex®6M Well Plate

Publication Date: November 5, 2022

Generation of non-human primate CAR Tregs using artificial antigen-presenting cells, simian tropic lentiviral vectors, and antigen-specific restimulation

This protocol shows how to manufacture clinical-sized doses of antigen-specific CAR regulatory T cells from Cynomolgus macaque blood. Tregs are sorted stringently, as the top 1%–2% of CD25+ CD127- cells among CD4+ CD8- cells, then stimulated with irradiated K562 artificial antigen-presenting cells and IL-2, transduced with a simian tropic lentiviral vector, and restimulated with Bw6-expressing K562 cells. From 25,000 to 100,000 sorted Tregs, 500–1000 × 10^6 cells are expected by day 18–21, with more than 80% FoxP3+, Helios+ and CAR+. CAR+ cells increased from 32.4% after the first stimulation to 91.7% after the third. Batches are checked with LAP activation, where more than 30% LAP+ cells…

Download Now →

Author: Gavin I. Ellis, Mosha Z. Deng +7 more